Currentselect_healthPolicy CCP.1278

Platelet rich plasma for nonhealing diabetic wounds

Customize your policy alerts

Sign up for select_health Policy CCP.1278 alerts

Get alerted when Policy CCP.1278 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy governs coverage of platelet-rich plasma (PRP) for chronic nonhealing diabetic wounds for Select Health of South Carolina members, specifying when PRP is considered medically necessary as an adjunct and required documentation and limits for continued use.

Policy Summary

Payerselect_health

PolicyPlatelet rich plasma for nonhealing diabetic wounds

Policy CodePolicy CCP.1278

Change TypeNo material change

Effective DateFeb 1, 2022

Last ReviewFeb 1, 2026

Next Review DateJun 1, 2027

Key ActionDocument lack of healing progress after standard wound care and use FDA 510(k)-cleared devices for PRP; reevaluate effectiveness at 20 weeks.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

20reevaluation timepoint (weeks)

<40%healing threshold

Multiple meta-analysesevidence base

G0465related HCPCS code

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

Currentselect_healthPolicy CCP.1278

Platelet rich plasma for nonhealing diabetic wounds

Customize your policy alerts

Sign up for select_health Policy CCP.1278 alerts

Get alerted when Policy CCP.1278 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

Payerselect_health

PolicyPlatelet rich plasma for nonhealing diabetic wounds

Policy CodePolicy CCP.1278

Change TypeNo material change

Effective DateFeb 1, 2022

Last ReviewFeb 1, 2026

Next Review DateJun 1, 2027

Key ActionDocument lack of healing progress after standard wound care and use FDA 510(k)-cleared devices for PRP; reevaluate effectiveness at 20 weeks.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

20reevaluation timepoint (weeks)

<40%healing threshold

Multiple meta-analysesevidence base

G0465related HCPCS code

Coverage Criteria for PRP in Chronic Diabetic Wounds

Adjunctive PRP for chronic diabetic wounds (covered when ALL criteria met)

Covered when ALL of the following are met

Adjunct PRP coverage criteria: (1) There is lack of healing progress with standard wound care (e.g., offloading, infection control, glycemic control, and wound bed preparation including debridement). Generally defined as ulcer reduction of less than 40% after at least four weeks of standard therapy.< 40% reduction after ≥4 weeks of standard therapy

Required documentation: wound history, recurrence, and wound characteristics (location, staging, size, base, exudates, infection, surrounding skin, pain). Effectiveness should be reevaluated at 20 weeks; continuation beyond 20 weeks requires secondary medical review.

Adjunct PRP coverage criteria: (2) Platelet-rich plasma is prepared using devices that are U.S. Food and Drug Administration (510(k))-cleared for management of exuding cutaneous wounds, such as diabetic ulcers.

Select Health considers platelet-rich plasma (PRP) investigational and not medically necessary for all clinical indications except when used as an adjunct for chronic diabetic wounds that meet the policy criteria. Coverage is allowed only when both of the following conditions are satisfied: (1) there is documented lack of healing progress with standard wound care (for example, offloading, infection control, glycemic control, and wound bed preparation including debridement), and (2) the PRP is prepared using a device that is U.S. FDA 510(k)-cleared for management of exuding cutaneous wounds such as diabetic ulcers.

Use of PRP for any other clinical indications beyond adjunctive treatment of chronic diabetic wounds that meet the above criteria is investigational and not medically necessary and therefore not covered under this policy.

Coding, Codes, and Healing Thresholds

Regulatory / CFR referencesmixed

21CFR640.34	Regulation cited for systems used to separate out platelets
21CFR864.9245	Regulation cited for systems producing platelet-rich preparations intended to be mixed with bone graft materials

Related Codes (most commonly submitted)HCPCS

G0465

Autologous platelet rich plasma (PRP) or other blood-derived product for diabetic chronic wounds/ulcers, using an FDA-cleared device for this indication (includes as applicable administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment)

inv-06: Healing progress threshold — ulcer reduction < 40% after ≥4 weeks of standard therapy

Healing progress thresholdUlcer reduction < 40% after ≥4 weeks of standard therapy

Standard therapy examplesOffloading, infection control, glycemic control, and wound bed preparation including debridement

Source guidanceWound Healing Society (2017) definition used by policy

inv-07: Reevaluation timepoint — 20 weeks

Reevaluation timepointEffectiveness should be reevaluated at 20 weeks of treatment

Continuation beyond timepointContinuation of treatment beyond 20 weeks requires secondary medical review

Provider Requirements, Prior Authorization, and Billing Guidance

Prior Authorization

Prior authorization and continuation review required

PRP allowed only when lack of healing progress with standard wound care is documented; effectiveness must be reevaluated at 20 weeks and continuation beyond 20 weeks requires secondary medical review.

Lack of healing progress generally defined as <40% ulcer reduction after ≥4 weeks of standard therapy.
PRP must be prepared using U.S. FDA 510(k)-cleared devices for exuding cutaneous wounds (e.g., diabetic ulcers).

Billing Rule

Bill PRP treatments using G0465 when applicable

When billing autologous PRP or other blood‑derived products for diabetic chronic wounds using an FDA‑cleared device, submit HCPCS code G0465 per treatment; this code description includes administration, dressings, phlebotomy, centrifugation or mixing, and all preparatory procedures.

Background and Rationale

Platelets contain numerous growth factors and bioactive proteins that contribute to tissue repair and wound healing. Platelet-rich plasma (PRP) is a blood-derived concentrate with higher platelet and growth factor concentrations than peripheral blood, prepared by centrifugation and used with the intent of enhancing local healing. The therapeutic rationale for PRP in chronic diabetic wounds is that delivering a concentrated mixture of platelets and their growth factors to a nonhealing ulcer may stimulate cellular processes involved in tissue repair and improve healing when standard wound care has failed.

Definitions

inv-17: Platelet-rich plasma (PRP) definition — blood-derived concentrate produced via centrifugation

DefinitionBlood-derived concentrate with a higher concentration of platelets and growth factors than peripheral blood, produced via centrifugation and (typically) activation

Preparation methodsTwo-stage centrifugation process to separate platelets from plasma and red blood cells; may include activation to form a fibrin network

inv-18: Lack of healing progress — defined as <40% reduction after ≥4 weeks of standard therapy

Lack of healing progress (policy definition)Generally defined as ulcer reduction of less than 40% after at least four weeks of standard therapy

When to consider adjuvant therapyReassess wounds that do not demonstrate this level of healing progress and consider selective adjunctive agents

Standard therapy examples

Policy Summary

Payerselect_health

PolicyPlatelet rich plasma for nonhealing diabetic wounds

Policy CodePolicy CCP.1278

Change TypeNo material change

Effective DateFeb 1, 2022

Last ReviewFeb 1, 2026

Next Review DateJun 1, 2027

Key ActionDocument lack of healing progress after standard wound care and use FDA 510(k)-cleared devices for PRP; reevaluate effectiveness at 20 weeks.

SourceLink

On This Page

Evidence citationQu (2020) referenced in policy for the 20-week reevaluation

Step Therapy

Conservative therapy must be tried and documented first

Standard wound care (e.g., offloading, infection control, glycemic control, wound bed preparation including debridement) must be attempted and documented prior to PRP.

Document specific conservative measures tried and duration before PRP is initiated.
Demonstrate lack of adequate healing despite these measures (see <40% reduction threshold).

Note

Policy history — 2/2022 coverage modification noted

Policy history: coverage modified in 2/2022 (references and coverage language updated previously in 2017–2021 and repeatedly reviewed thereafter). No explicit additional step therapy requirements are stated in the policy text.

Documentation Required

Document wound history, recurrence, and detailed wound characteristics

Required documentation for review must include wound history, recurrence, and wound characteristics (location, staging, size, base, exudate, infection, condition of surrounding skin, and pain).

Include objective measurements of wound size and serial assessments to show healing rate.
Tie documentation to the statement that rate of healing should be evaluated to determine if treatment is optimal.

Billing Rule

Follow coding manuals and match coding to service details

Providers are expected to consult coding manuals and bill according to appropriate codes; the policy lists commonly submitted code G0465 and notes it includes administration and preparatory procedures per treatment.

Ensure submitted codes and claim documentation match the service provided (device use, phlebotomy, centrifugation, administration).

Denial Risk

Coverage limited to adjunctive PRP for chronic diabetic wounds meeting criteria

PRP is considered investigational and not medically necessary for clinical indications other than as an adjunct for chronic diabetic wounds that meet the policy criteria; treatments not meeting the criteria risk denial.

Denial Risk

Coding and documentation mismatches tied to G0465 can lead to denial

Claims for autologous PRP may be audited against commonly submitted code G0465; lack of appropriate coding or documentation tying the service to the policy criteria could trigger denial.

Be prepared to provide documentation linking the billed G0465 service to: FDA‑cleared device use, attempted standard care with inadequate healing, and the wound characteristics required by policy.

Includes offloading, infection control, glycemic control, and wound bed preparation including debridement

inv-19: Autologous platelet-rich plasma (PRP) — PRP prepared from the patient's own blood using an FDA-cleared device

Autologous PRP definitionPRP or other blood-derived product prepared from the patient’s own blood using an FDA-cleared device for the indication (includes administration, dressings, phlebotomy, centrifugation or mixing, and preparatory procedures, per treatment)

Billing code commonly usedG0465 commonly submitted for autologous PRP for diabetic chronic wounds (includes administration and preparatory procedures)

Regulatory noteSystems and clinical use are regulated by FDA (see 21CFR640.34 and related regs for platelet separation systems)